logo-loader

Redx Pharma's CSO Richard Armer outlines development ambitions and clinical targets

Published: 09:30 20 Nov 2018 GMT

Redx Pharma Plc's (LON:REDX) chief scientific officer Richard Armer sat down with Proactive London's Andrew Scott to discuss the opportunities ahead for their cancer and fibrosis portfolios.

Redx is ready to begin first-in-man trials of lead oncology drug, RXC004, in the first half of next year.

Putative fibrosis treatment RXC006 is expected to enter the clinic the year after.

Redx Pharma achieves milestone with dosing of first participant in Phase 1...

  Redx Pharma PLC (AIM:REDX) CEO Lisa Anson discusses the enrollment of the first participant in its RXC008 Phase 1 clinical trial in an interview with Proactive's Stephen Gunnion. RXC008 is a 'first-in-class' ROCK inhibitor, designed to be gut-restricted, targeting fibrostenotic Crohn's...

2 weeks, 6 days ago